What are Recombinant clotting factor drugs?

Recombinant clotting factor drugs are pharmacologic agents that share a common mechanism (typically targeting Factor VIII (antihemophilic factor)). 3 are currently marketed, with 3 more in clinical development.

What are the marketed Recombinant clotting factor drugs?

Marketed Recombinant clotting factor drugs include ReFacto, Recombinant Factor VIII (rAHF), Recombinant factor IX.

Recombinant clotting factor

3 marketed 3 in Phase 3

This page covers all Recombinant clotting factor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Factor VIII (antihemophilic factor), Coagulation Factor VIII, Coagulation factor IX (F9).

Targets

Factor VIII (antihemophilic factor) · Coagulation Factor VIII · Coagulation factor IX (F9) · Factor VIII (coagulation factor VIII) · Factor X (coagulation factor X) · Factor VIII / Intrinsic tenase complex

Marketed (3)

ReFacto · Wyeth is now a wholly owned subsidiary of Pfizer · Hematology
ReFacto is a recombinant antihemophilic factor (Factor VIII) that replaces deficient or dysfunctional clotting factor VIII to restore blood coagulation in hemophilia A patients.
Recombinant Factor VIII (rAHF) · Baxalta now part of Shire · Hematology
Recombinant Factor VIII replaces the missing or deficient clotting factor VIII protein to restore the intrinsic coagulation pathway and enable normal blood clot formation.
Recombinant factor IX · Baxalta now part of Shire · Hematology
Recombinant factor IX replaces the missing or deficient clotting factor IX to restore the intrinsic coagulation pathway and enable normal blood clot formation.

Phase 3 pipeline (3)

Human cl rhFVIII · Octapharma · Hematology
Human cl rhFVIII is a recombinant human Factor VIII that replaces deficient or dysfunctional clotting factor VIII to restore blood coagulation in hemophilia A patients.
Coagadex(R) · Kedrion S.p.A. · Hematology
Coagadex is a recombinant human vitamin K-dependent clotting factor X that replaces deficient or dysfunctional Factor X to restore blood coagulation.
Factor VIII (rFVIIIFc) · Bioverativ Therapeutics Inc. · Hematology
rFVIIIFc is a recombinant Factor VIII protein fused to the Fc domain of human immunoglobulin G, which replaces deficient clotting Factor VIII to restore hemostasis in hemophilia A patients.